
U.S. DNA manufacturing Market Size, Share, Trends, Industry Analysis Report By Type (Plasmid DNA, Synthetic DNA), By Grade, By Application, By End Use – Market Forecast, 2025–2034
Description
The us dna manufacturing market size is expected to reach USD 11.72 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. DNA Manufacturing Market Size, Share, Trends, Industry Analysis Report By Type (Plasmid DNA, Synthetic DNA), By Grade, By Application, By End Use – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
DNA manufacturing involves the synthetic production of deoxyribonucleic acid (DNA) sequences for use in biotechnology, medicine, and various research applications. Companies synthesize custom DNA strands through chemical processes, enabling advancements in gene therapy, vaccine development, and synthetic biology. DNA manufacturing allows scientists to design and produce genetic molecules for applications such as CRISPR-based gene editing and diagnostic tools. The growing demand for personalized medicine and biopharmaceuticals is driving the expansion of DNA manufacturing, with innovations reducing costs and improving precision. However, ethical concerns, regulatory hurdles, and the complexity of large-scale production pose challenges to the U.S. DNA manufacturing market growth.
The U.S. DNA manufacturing market is growing due to increasing healthcare demands, an aging population, and the rise of chronic diseases. Advances in biotechnology, such as mRNA vaccines and therapeutics, are pushing innovation in the market, while government incentives and private investments are driving market growth. The shift toward personalized medicine and orphan drugs is creating lucrative opportunities for manufacturers.
U.S. DNA Manufacturing Market Report Highlights
In terms of type, the plasmid DNA segment accounted for a major market share in 2024. Pharmaceutical and biotechnology companies drove strong demand for plasmid DNA due to its critical role in cell and gene therapies, DNA vaccines, and viral vector production.
Based on grade, the GMP grade segment held the largest market share in 2024 due to increasing demand for high-quality synthetic DNA in therapeutic applications, including mRNA vaccines, gene therapies, and cell-based treatments.
In terms of application, the cell & gene therapy segment dominated the market share in 2024 due to increasing advancements in CRISPR-based gene editing, CAR-T cell therapies, and viral vector production.
Based on end use, the contract research organizations segment is projected to grow at a robust pace in the coming years, owing to the growing trend of outsourcing in drug discovery and clinical trials.
A few key market players include AGC Biologics, Bionova Scientific, Catalent, Charles River Laboratories, Danaher, Eurofins Genomics, GenScript, Lonza, Thermo Fisher Scientific, Twist Bioscience, and VGXI, Inc.
Polaris Market Research has segmented the U.S. DNA manufacturing market report on the basis of type, grade, application, and end use:
By Type Outlook (Revenue, USD Billion, 2020–2034)
Plasmid DNA
Synthetic DNA
Gene Synthesis
Oligonucleotide Synthesis
By Grade Outlook (Revenue, USD Billion, 2020–2034)
GMP Grade
R&D Grade
By Application Outlook (Revenue, USD Billion, 2020–2034)
Cell & Gene Therapy
Vaccines
Oligonucleotide-based drugs
Others
By End Use Outlook (Revenue, USD Billion, 2020–2034)
Pharmaceutical and Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
DNA manufacturing involves the synthetic production of deoxyribonucleic acid (DNA) sequences for use in biotechnology, medicine, and various research applications. Companies synthesize custom DNA strands through chemical processes, enabling advancements in gene therapy, vaccine development, and synthetic biology. DNA manufacturing allows scientists to design and produce genetic molecules for applications such as CRISPR-based gene editing and diagnostic tools. The growing demand for personalized medicine and biopharmaceuticals is driving the expansion of DNA manufacturing, with innovations reducing costs and improving precision. However, ethical concerns, regulatory hurdles, and the complexity of large-scale production pose challenges to the U.S. DNA manufacturing market growth.
The U.S. DNA manufacturing market is growing due to increasing healthcare demands, an aging population, and the rise of chronic diseases. Advances in biotechnology, such as mRNA vaccines and therapeutics, are pushing innovation in the market, while government incentives and private investments are driving market growth. The shift toward personalized medicine and orphan drugs is creating lucrative opportunities for manufacturers.
U.S. DNA Manufacturing Market Report Highlights
In terms of type, the plasmid DNA segment accounted for a major market share in 2024. Pharmaceutical and biotechnology companies drove strong demand for plasmid DNA due to its critical role in cell and gene therapies, DNA vaccines, and viral vector production.
Based on grade, the GMP grade segment held the largest market share in 2024 due to increasing demand for high-quality synthetic DNA in therapeutic applications, including mRNA vaccines, gene therapies, and cell-based treatments.
In terms of application, the cell & gene therapy segment dominated the market share in 2024 due to increasing advancements in CRISPR-based gene editing, CAR-T cell therapies, and viral vector production.
Based on end use, the contract research organizations segment is projected to grow at a robust pace in the coming years, owing to the growing trend of outsourcing in drug discovery and clinical trials.
A few key market players include AGC Biologics, Bionova Scientific, Catalent, Charles River Laboratories, Danaher, Eurofins Genomics, GenScript, Lonza, Thermo Fisher Scientific, Twist Bioscience, and VGXI, Inc.
Polaris Market Research has segmented the U.S. DNA manufacturing market report on the basis of type, grade, application, and end use:
By Type Outlook (Revenue, USD Billion, 2020–2034)
Plasmid DNA
Synthetic DNA
Gene Synthesis
Oligonucleotide Synthesis
By Grade Outlook (Revenue, USD Billion, 2020–2034)
GMP Grade
R&D Grade
By Application Outlook (Revenue, USD Billion, 2020–2034)
Cell & Gene Therapy
Vaccines
Oligonucleotide-based drugs
Others
By End Use Outlook (Revenue, USD Billion, 2020–2034)
Pharmaceutical and Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
Table of Contents
129 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. U.S. Aerospace Testing Market Insights
- 4.1. U.S. Aerospace Testing Market – Market Snapshot
- 4.2. U.S. Aerospace Testing Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Demand for New Aircraft and Components
- 4.2.1.2. Strict Aviation Safety Regulations and Technological Advancements
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High capital investment requirements
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. U.S. Aerospace Testing Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. U.S. Aerospace Testing Market, by Testing Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. U.S. Aerospace Testing Market, by Testing Type, 2020–2034 (USD Billion)
- 5.3. Material Testing
- 5.3.1. U.S. Aerospace Testing Market, by Material Testing, by Region, 2020–2034 (USD Billion)
- 5.4. Environmental Testing
- 5.4.1. U.S. Aerospace Testing Market, by Environmental Testing, by Region, 2020–2034 (USD Billion)
- 5.5. Structural/Component Testing
- 5.5.1. U.S. Aerospace Testing Market, by Structural/Component Testing, by Region, 2020–2034 (USD Billion)
- 5.6. Electromagnetic Compatibility (EMC) Testing
- 5.6.1. U.S. Aerospace Testing Market, by Electromagnetic Compatibility (EMC) Testing, by Region, 2020–2034 (USD Billion)
- 5.7. Software Testing
- 5.7.1. U.S. Aerospace Testing Market, by Software Testing, by Region, 2020–2034 (USD Billion)
- 5.8. Others
- 5.8.1. U.S. Aerospace Testing Market, by Others, by Region, 2020–2034 (USD Billion)
- 6. U.S. Aerospace Testing Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. U.S. Aerospace Testing Market, by Application, 2020–2034 (USD Billion)
- 6.3. Aircraft Structures
- 6.3.1. U.S. Aerospace Testing Market, by Aircraft Structures, by Region, 2020–2034 (USD Billion)
- 6.4. Propulsion Systems
- 6.4.1. U.S. Aerospace Testing Market, by Propulsion Systems, by Region, 2020–2034 (USD Billion)
- 6.5. Interiors
- 6.5.1. U.S. Aerospace Testing Market, by Interiors, by Region, 2020–2034 (USD Billion)
- 6.6. Space Systems
- 6.6.1. U.S. Aerospace Testing Market, by Space Systems, by Region, 2020–2034 (USD Billion)
- 6.7. Avionics & Electronics
- 6.7.1. U.S. Aerospace Testing Market, by Avionics & Electronics, by Region, 2020–2034 (USD Billion)
- 7. U.S. Aerospace Testing Market, by Aviation Type
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. U.S. Aerospace Testing Market, by Aviation Type, 2020–2034 (USD Billion)
- 7.3. Commercial Aviation
- 7.3.1. U.S. Aerospace Testing Market, by Commercial Aviation, by Region, 2020–2034 (USD Billion)
- 7.4. Military Aviation
- 7.4.1. U.S. Aerospace Testing Market, by Military Aviation, by Region, 2020–2034 (USD Billion)
- 7.5. Space Exploration
- 7.5.1. U.S. Aerospace Testing Market, by Space Exploration, by Region, 2020–2034 (USD Billion)
- 7.6. Others
- 7.6.1. U.S. Aerospace Testing Market, by Others, by Region, 2020–2034 (USD Billion)
- 8. U.S. Aerospace Testing Market, by End Use
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. U.S. Aerospace Testing Market, by End Use, 2020–2034 (USD Billion)
- 8.3. OEMs
- 8.3.1. U.S. Aerospace Testing Market, by OEMs, by Region, 2020–2034 (USD Billion)
- 8.4. MROs (Maintenance, Repair & Overhaul)
- 8.4.1. U.S. Aerospace Testing Market, by MROs (Maintenance, Repair & Overhaul), by Region, 2020–2034 (USD Billion)
- 8.5. Airlines & Defense Operators
- 8.5.1. U.S. Aerospace Testing Market, by Airlines & Defense Operators, by Region, 2020–2034 (USD Billion)
- 8.6. Government & Space Agencies
- 8.6.1. U.S. Aerospace Testing Market, by Government & Space Agencies, by Region, 2020–2034 (USD Billion)
- 8.7. Others
- 8.7.1. U.S. Aerospace Testing Market, by Others, by Region, 2020–2034 (USD Billion)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. Applus Services, S.A.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. The Boeing Company
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Element Materials Technology
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. GE Aerospace
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Intertek Group plc
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Laboratory Testing Inc.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Lockheed Martin Corporation
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. MISTRAS Group, Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Northrop Grumman Corporation
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. RTX Corporation (Collins Aerospace)
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. TÜV SÜD AG
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.